Worse airflow obstruction but not type 2 biomarkers identifies super-responders to tezepelumab in real-life

Research output: Contribution to journal › Letter › peer-review

Original language	English
Journal	Annals of Allergy, Asthma and Immunology
Early online date	24 Mar 2025
DOIs	https://doi.org/10.1016/j.anai.2025.03.013
Publication status	E-pub ahead of print - 24 Mar 2025

Keywords

@article{be056c085b1041748fa82acaba5aab80,

title = "Worse airflow obstruction but not type 2 biomarkers identifies super-responders to tezepelumab in real-life",

keywords = "Asthma, super-responder, tezepelumab, spirometry",

author = "Robert Greig and Rory Chan and Brian Lipworth",

note = "{\textcopyright} 2025 American College of Allergy, Asthma & Immunology.",

year = "2025",

month = mar,

day = "24",

doi = "10.1016/j.anai.2025.03.013",

language = "English",

journal = "Annals of Allergy, Asthma and Immunology",

issn = "1081-1206",

publisher = "American College of Allergy, Asthma and Immunology",

}

TY - JOUR

T1 - Worse airflow obstruction but not type 2 biomarkers identifies super-responders to tezepelumab in real-life

AU - Greig, Robert

AU - Chan, Rory

AU - Lipworth, Brian

PY - 2025/3/24

Y1 - 2025/3/24

KW - Asthma

KW - super-responder

KW - tezepelumab

KW - spirometry

U2 - 10.1016/j.anai.2025.03.013

DO - 10.1016/j.anai.2025.03.013

M3 - Letter

SN - 1081-1206

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

ER -